Holowesko Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,000
| Closed | -$588K | – | 32 |
|
|
2025
Q4 | $588K | Hold |
12,000
| – | – | 0.2% | 26 |
|
|
2025
Q3 | $518K | Hold |
12,000
| – | – | 0.19% | 24 |
|
|
2025
Q2 | $461K | Hold |
12,000
| – | – | 0.15% | 27 |
|
|
2025
Q1 | $465K | Hold |
12,000
| – | – | 0.17% | 26 |
|
|
2024
Q4 | $406K | Sell |
12,000
-40,000
| -77% | -$1.44M | 0.19% | 24 |
|
|
2024
Q3 | $2.13M | Hold |
52,000
| – | – | 1.12% | 16 |
|
|
2024
Q2 | $2M | Hold |
52,000
| – | – | 1.07% | 16 |
|
|
2024
Q1 | $2.23M | Hold |
52,000
| – | – | 0.83% | 22 |
|
|
2023
Q4 | $1.93M | Hold |
52,000
| – | – | 0.65% | 22 |
|
|
2023
Q3 | $1.89M | Hold |
52,000
| – | – | 0.8% | 19 |
|
|
2023
Q2 | $1.85M | Hold |
52,000
| – | – | 0.81% | 17 |
|
|
2023
Q1 | $1.85M | Hold |
52,000
| – | – | 0.97% | 18 |
|
|
2022
Q4 | $1.83M | Hold |
52,000
| – | – | 0.88% | 21 |
|
|
2022
Q3 | $1.53M | Hold |
52,000
| – | – | 0.86% | 20 |
|
|
2022
Q2 | $2.83M | Hold |
52,000
| – | – | 1.48% | 20 |
|
|
2022
Q1 | $2.83M | Hold |
52,000
| – | – | 1.36% | 21 |
|
|
2021
Q4 | $2.87M | Hold |
52,000
| – | – | 1.17% | 18 |
|
|
2021
Q3 | $2.48M | Hold |
52,000
| – | – | 0.92% | 21 |
|
|
2021
Q2 | $2.59M | Buy |
52,000
+4,000
| +8% | +$192K | 0.66% | 19 |
|
|
2021
Q1 | $2.14M | Hold |
48,000
| – | – | 0.57% | 22 |
|
|
2020
Q4 | $2.21M | Sell |
48,000
-213,600
| -82% | -$9.81M | 0.59% | 23 |
|
|
2020
Q3 | $12.3M | Hold |
261,600
| – | – | 2.07% | 13 |
|
|
2020
Q2 | $13.3M | Sell |
261,600
-26,400
| -9% | -$1.35M | 1.6% | 16 |
|
|
2020
Q1 | $13.6M | Buy |
288,000
+280,000
| +3,500% | +$14.9M | 1.49% | 18 |
|
|
2019
Q4 | $470K | Hold |
8,000
| – | – | 0.03% | 30 |
|
|
2019
Q3 | $427K | Hold |
8,000
| – | – | 0.03% | 24 |
|
|
2019
Q2 | $400K | Hold |
8,000
| – | – | 0.03% | 23 |
|
|
2019
Q1 | $418K | Hold |
8,000
| – | – | 0.03% | 25 |
|
|
2018
Q4 | $382K | Hold |
8,000
| – | – | 0.03% | 25 |
|
|
2018
Q3 | $402K | Hold |
8,000
| – | – | 0.03% | 25 |
|
|
2018
Q2 | $403K | Hold |
8,000
| – | – | 0.03% | 27 |
|
|
2018
Q1 | $391K | Hold |
8,000
| – | – | 0.03% | 31 |
|
|
2017
Q4 | $355K | Hold |
8,000
| – | – | 0.02% | 30 |
|
|
2017
Q3 | $406K | Hold |
8,000
| – | – | 0.03% | 26 |
|
|
2017
Q2 | $431K | Hold |
8,000
| – | – | 0.03% | 31 |
|
|
2017
Q1 | $422K | Buy |
+8,000
| New | +$406K | 0.03% | 31 |
|
Other funds holding GSK
JEST
Holowesko Partners's GSK Position: Q1 2026 in Review
Holowesko Partners sold out of GSK (GSK) in Q1 2026, closing a stake of 12,000 shares — an estimated $588K sold.
Holowesko Partners first reported a position in GSK in Q1 2017 and held it in 36 quarters. The position peaked at $13.6M in Q1 2020. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Holowesko Partners reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
- Holowesko Partners sold 12,000 GSK shares in Q1 2026, an estimated $588K.
- Holowesko Partners first reported a position in GSK in Q1 2017 and held it in 36 quarters.
- Holowesko Partners's GSK position peaked at $13.6M in Q1 2020.
- 1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Holowesko Partners's 13F filing for Q1 2026, filed 13 May 2026.